| Document |
Document Title |
|
WO/2003/024529A1 |
There are provided sarcodictyin derivatives or pharmaceutically acceptable salts thereof, which are characterized by a simplified chemical structure and have anti-tumor activity. A process for their preparation, the pharmaceutical compos...
|
|
WO/2003/024985A2 |
Epoxy resin polyglycoside-based cured polymers and process for the preparation are described. A particular epoxy resin precursor is the diglycidyl ether of bisphenol A. A particular glucose based polymer is a glucose malic acid ester-vin...
|
|
WO/2003/022860A1 |
Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.
|
|
WO/2003/020736A1 |
The antibiotic drug clindamycin is provided as a crystalline free base. Three polymorphic/pseudopolymorphic forms of crystalline clindamycin free base are disclosed. Also provided are pharmaceutical compositions comprising crystalline cl...
|
|
WO/2003/017949A2 |
Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuropro...
|
|
WO/2003/018535A2 |
The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compo...
|
|
WO/2003/018602A1 |
The inventive ferrocene mannose derivatives have the following general structural formula: Wherein n=1-6. Said compositions are capable to activate the killing of intracellularly localised microorganisms.
|
|
WO/2003/016469A2 |
$i(In vitro)/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel comp...
|
|
WO/2003/016326A1 |
A glycolipid useful for treatments for autoimmune diseases&semi and a remedy for autoimmune diseases which contains the glycolipid as an active ingredient. The glycolipid is represented by the following formula (I): (I) wherein R1 repres...
|
|
WO/2003/016325A1 |
A modified metal ion compound reduced in industrially undesirable properties inherent in metal ion compounds, such as deliquescence, reducing ability, oxidizing ability, and poor solubility in water&semi a process for producing the produ...
|
|
WO/2003/014249A1 |
A gellant for hydrogel formation which has the ability to form a gel in both an organic solvent and water. It is represented by the following chemical formula: (I) wherein A represents a residue of a sugar and R represents alkyl.
|
|
WO/2003/013502A1 |
Compounds which mimic the chemical and/or biological activity of discodermolide are provided.
|
|
WO/2003/013529A1 |
A salt formed from paroxetine hydrochloride and ammonium glycyrrhyzinate masks the bitter taste of paroxetine and has a distinctive liquorice flavour.
|
|
WO/2003/014135A1 |
The present invention relates to a novel process for the preparation of acarbose. Said process comprises the steps of: 1) acidifying a fermentation broth containing an acarbose; 2) removing particulates from the fermentation broth; 3) ad...
|
|
WO/2003/014296A2 |
Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them...
|
|
WO/2003/011879A1 |
$i(In vitro)/cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel comp...
|
|
WO/2003/011880A1 |
A glucopyranosyloxybenzylbenzene derivative represented by the general formula (I) (wherein R1 represents hydrogen, hydroxy, optionally substituted amino, cyano, carbamoyl, optionally substituted lower alkyl, optionally substituted lower...
|
|
WO/2003/010178A1 |
The invention concerns disaccharides of formula (I) derived from $g(a)-maltosyl fluoride, wherein R?1¿ and R?2¿ are such as defined in Claim 1. Said disaccharides are useful as glycosyl donors in transglycosylation reactions catalysed ...
|
|
WO/2003/008430A2 |
This invention relates to porphyrin compounds used to destroy or impair the functioning of a target biological material in photodynamic therapy, in particular against virus, tumoral cells, bacteria, tumorous tissues. The invention also r...
|
|
WO/2003/008429A2 |
There are provided a method for making highly purified crystals of anthracycline derivatives, and a new crystalline form of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin, useful in the treatment of tumors.
|
|
WO/2003/006474A2 |
The invention relates to a method for producing peracylated 1-O-glycosides of general formula (I) or salts thereof, wherein sugar?1¿ is a monosaccharide which is functionalised in the 1-OH-position, R represents methyl, ethyl, propyl is...
|
|
WO/2003/006028A1 |
Immunosuppressants each containing as the active ingredient at least one member selected from the group consisting of compounds of the general formula (1) and pharmaceutically acceptable salts thereof: (1) wherein R101 is an acyl residue...
|
|
WO/2003/004098A1 |
The present invention provides a composition for topical administration comprising an interleukin 2 inhibitor and an antimicrobial agent as active ingredients thereof, wherein said interleukin 2 inhibitor contains a tricyclo compound as ...
|
|
WO/2003/004466A2 |
The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of type 1 and type 2 agents or a sin...
|
|
WO/2003/004005A1 |
The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advanta...
|
|
WO/2003/002585A1 |
The invention relates to novel [4-(4-cyanobenzoyl)phenyl]glycopyranoside derivatives having formula (I), wherein X represents a hydrogen atom or a methyl group and R represents a glycopyranosyl group. Said compounds have an anti-atheroma...
|
|
WO/2003/002066A2 |
[00138] The invention provides compositions, including pharmaceuticals, comprising glycosylated kinamycins. The compositions and methods of the invention can be used to treat infections, i.e., as antibiotics, and as anti-tumor agents. Th...
|
|
WO/2003/002563A1 |
Compounds of formula (I) wherein: W¿I? and W¿2? represent, with the carbon atoms to which they are bound, a phenyl group or a pyridinyl group, and at least one of the groups W¿1? or W¿2? represent a pyridinyl group; R¿1? and R¿2? e...
|
|
WO/2003/002586A1 |
The invention relates to novel [4-(4-cyanobenzoyl)phenyl] glycofuranoside derivatives having formula (I), wherein R represents a glycofuranosyl group. Said compounds have an anti-atheromatous activity.
|
|
WO/2003/002127A1 |
The present invention relates to the use of a glycosidase inhibitor for the manufacture of a medicament for the treatment of a disease, wherein glycosidase enzymes hydrolyze glycoconjugates of a patient to reveal neutral glycan receptors...
|
|
WO/2003/002584A1 |
Galactosylceramide analogs represented by the following general formula (1) or (2): (1) (2) wherein X and Y represent each S or O&semi R1 and R2 represent each C9−35 alkyl or alkenyl&semi and R3 represents C2−30 alkyl or alkenyl. Eas...
|
|
WO/2003/000710A1 |
The invention relates to alkyl- and/or alkenyloligoglycoside preparations that have a magnesium salt concentration of less than 10 ppm based on the entire composition. The inventive preparations are obtained by adjusting alkyl- and/or al...
|
|
WO/2003/000922A2 |
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
|
|
WO/2003/000711A1 |
This invention provides analogs of eleutherobin and the eleuthesides modified at the C-11 position or comprising an epoxide functionality from C-11 to C-12. C-11 to C-12 is an ideal location for conjugating functional moieties to the ele...
|
|
WO/2002/103025A1 |
A sulfated saccharide represented by the following general formula: [A]−(6SO3−GlcNAc)−[C]−R wherein (6SO3−GlcNAc) represents a 6−sulfated N−acetylglucosamine residue&semi [A] represents hydroxy or a saccharide residue&semi ...
|
|
WO/2002/102816A1 |
The invention relates to a method for producing perbenzylated 1-O-glycosides of general formula I or the salts thereof. In said formula, Sugar?1¿ represents a monosaccharide functionalised in the 1-OH-position, R represents benzyl, n re...
|
|
WO/2002/102416A2 |
The invention relates to acetyl- or benzoyl-protected bromoalkyl-$g(b)-D-glucosides and glycoconjugates that can be structured by reacting the acetyl- or benzoyl-protected bromoalkyl-$g(b)-D-glucosides with isoquinolinedion structures. T...
|
|
WO/2002/102325A2 |
The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal...
|
|
WO/2002/102817A1 |
Anthracycline glycosides of formula I, as reported in the description, wherein R is hydrogen, hydroxy or methoxy, R¿1? and R¿2?, which are the same or different, are independently hydrogen or hydroxy, and the pharmaceutically acceptabl...
|
|
WO/2002/100401A1 |
The invention relates to indirubin derivatives of formula (I) that, by establishing a basic side chain in the 5-position, contain a radically increased solubility with a simultaneous improvement in the biological activity. The invention ...
|
|
WO/2002/100537A2 |
The invention relates to novel ruthenium catalysts which can be obtained by: 1) single or multiple treatment of an amorphous silicon-dioxide-based carrier material with a halogen-free aqueous solution of a low-molecular ruthenium compoun...
|
|
WO/2002/098885A1 |
The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and the...
|
|
WO/2002/098893A1 |
A glucopyranosyloxypyrazole derivative represented by the following general formula (I), a pharmaceutically acceptable salt of the derivative, or a prodrug of either. (I) The compound has excellent inhibitory activity against human SGLT1...
|
|
WO/2002/096399A1 |
A lipolysis accelerator which has no peculiar scent or flavor, has excellent general-purpose properties, is effective in improving an obese constitution by accelerating adipose tissue diminution in the whole or a local part of the body o...
|
|
WO/2002/095393A2 |
A new method of designing and generating compounds having an increased probability of being drugs, drug candidates, or biologically active compounds, in particular having a therapeutic utility, is disclosed. The method consists of identi...
|
|
WO/2002/090369A2 |
The invention relates to a method for the production of surface active agent mixtures containing alkyl/ and/or alkenyl oligoglycoside/ether carboxylic acids. The invention is characterized in that an aqueous solution from at least one al...
|
|
WO/2002/090313A1 |
The invention relates to aloe-emodin (AE) derivatives and their use as anticancer drugs. Saids derivatives show a specific cytotoxicity to tumour cells, also of neuroectodermal origin, to which they may in particular act as aloe-emodin p...
|
|
WO/2002/087632A1 |
The invention relates to a wide variety of different methods and compositions that find use in high throughput screening applications utilizing magnetic resonance imaging (MRI) contrast agents.
|
|
WO/2002/085359A1 |
The present invention provides an agent for topical ophthalmic treatment of a human for ocular inflammatory diseases, containing a tricyclo compound as shown by the general formula (I) or its pharmaceutically acceptable salt as the activ...
|
|
WO/2002/086142A1 |
It is intended to provide a novel process for producing soyasapogenol B which is useful as a drug or a material for producing drugs. Sophoradiol employed as a starting material is treated with a hydroxylase originating in a plant to ther...
|
